Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders

https://doi.org/10.14412/2074-2711-2015-4-83-91

Full Text:

Abstract

The important task of nevrology is to improve the diagnosis of chronic progressive degenerative and vascular brain diseases – to detect them at the earliest stages. The paper presents current views on the non-dementia stages of brain diseases: moderate, mild, and subjective cognitive impairments. It sets forth data on their prevalence and clinical features and types, as well as international diagnostic criteria. There is evidence for the expediency of the earliest neuroprotective therapy to prevent dementia. A methodology for neuroprotective therapy is discussed; the available data on the long-term effect of intermittent treatment cycles with the vasotropic and neurometabolic drug tanakan are given.

About the Authors

V. V. Zakharov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Moscow 119021



N. V. Vakhnina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Moscow 119021



D. O. Gromova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Moscow 119021



N. E. Ter-Ovanesova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Moscow 119021



A. V. Tarapovskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery,

11, Rossolimo St., Moscow 119021



References

1. Petersen RS, Smith GE, Waring SC, et al Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 Mar;56(3):303-8.

2. American Psychiatric Association. Diagnostic and statistical manual of mental diseases. 5th edition (DSM-V). Washington D.C., London, Egnland; 2013. 947 P.

3. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 Sep;256(3):183-94.

4. Roberts RO, Geda YE, Knopman D, et al. The Mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69. doi: 10.1159/000115751. Epub 2008 Feb 7.

5. Unverzagt FW, Gao S, Baiyewu O, et al. Prevalence of cognitive impairment: date from Indianapolis study of health and aging. Neurology. 2001 Nov 13;57(9):1655-62.

6. Hanninen T, Hallikainen M, Toumainen S, et al. Prevalence of mild cognitive impairment: a pupulation based study in elderly subjects. Acta Neurol Scand. 2002 Sep;106(3):148-54.

7. Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2003 Oct;60(10):1385-9.

8. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiological study. Neurology. 2004 Jul 13;63(1):115-21.

9. DiCarlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italien elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007 May 29;68(22):1909-16.

10. Fisher P, Jungwirth S, Zehetmayer S, et al. Conversion of subtypes of mild cognitive impairment to Alzheimer’s disease. Neurology. 2007 Jan 23;68(4):288-91.

11. Mannly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in multiethnic community. Ann Neurol. 2008 Apr;63(4):494-506. doi: 10.1002/ana.21326.

12. Palmer K, Backman L, Winblad B, Fratiglioni L. Mild cognitive impairment in general population: occurrence and progression to Alzheimer’s disease. Am J Geriatr Psychiatry. 2008 Jul;16(7):603-11. doi: 10.1097/JGP.0b013e3181753a64.

13. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008 Mar 18;148(6):427-34.

14. Захаров ВВ. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журнал. 2006;11(2):27-32. [Zakharov VV. National program for research on the epidemiology and therapy of cognitive disorders in the elderly («Prometheus»). Nevrologicheskii zhurnal. 2006;11(2):27-32. (In Russ.)].

15. Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic vs community based cohorts. Arch Neurol. 2009 Sep;66(9):1151-7. doi: 10.1001/archneurol.2009.106.

16. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI and rates of progression to dementia. Neurology. 2004 Nov 23;63(10):1882-91.

17. Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology. 2006 Jul 25;67(2):229-34.

18. Ravaglia G, Forti P, Montesi F, et al. Mild cognitive impairment: epidemiology and dementia risk in elderly Italian population. J Am Geriatr Soc. 2008 Jan;56(1):51-8. Epub 2007 Nov 20.

19. Petersen RC, Knopman DS, Boeve BF, et al. Mild cognitive impairment: 10 years later. Arch Neurol. 2009 Dec;66(12):1447-55. doi: 10.1001/archneurol.2009.266.

20. Petersen RC. Early diagnosis of Alzheimer’s disease: is MCI too late? Curr Alzheimer Res. 2009 Aug;6(4):324-30.

21. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer’s disease neuroimaging initiative. In: Neuroimaging clinics of North America: Alzheimer’s disease: 100 years of progress. Petrella JR, Doraiswamy PM, editors. Philadelphia: Elsevier Saunders; 2005. P. 869-77.

22. Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006 Jan;63(1):38-46.

23. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer’s pathology and cerebral infarctions. Neurology. 2005 Mar 8;64(5):834-41.

24. Яхно НН, Преображенская ИС, Захаров ВВ и др. Распространенность когнитивных нарушений при неврологических заболеваниях (анализ работы специализированного амбулаторного приема). Неврология, нейропсихиатрия, психосоматика. 2012;4(2):30-5. [Yakhno NN, Preobrazhenskaya IS, Zakharov VV, et al. Prevalence of cognitive impairments in neurological diseases: Analysis of the activities of a specialized outpatient reception office. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2012;4(2):30-5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-378

25. Яхно НН, Левин ОС, Дамулин ИВ. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 2: когнитивные нарушения. Неврологический журнал. 2001;6(3):10-9. [Yakhno NN, Levin OS, Damulin IV. Correlation of clinical and MRI data with discirculatory encephalopathy. Message 2: cognitive impairment. Nevrologicheskii zhurnal. 2001;6(3):10-9. (In Russ.)].

26. Яхно НН, Захаров ВВ, Локшина АБ. Синдром умеренных когнитивных нарушений при дисциркуляторной энцефалопатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;105(2):13-7. [Yakhno NN, Zakharov VV, Lokshina AB. The syndrome of moderate cognitive disorders in dyscirculatory encephalopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;105(2):13-7. (In Russ.)].

27. Локшина АБ, Захаров ВВ. Лёгкие и умеренные когнитивные расстройства при дисциркуляторной энцефалопатии. Неврологический журнал. 2006;11(Приложение 1):57-63. [Lokshina AB, Zakharov VV. Light and moderate cognitive disorders in dyscirculatory encephalopathy. Nevrologicheskii zhurnal. 2006;11(S1):57-63. (In Russ.)].

28. Вахнина НВ, Никитина ЛЮ, Парфенов ВА. Постинсультные когнитивные нарушения. Журнал неврологии и психитарии им. С.С. Корсакова. 2008;22(Приложение 1):16-21. [Vakhnina NV, Nikitina LYu, Parfenov VA. Post-stroke cognitive impairment. Zhurnal nevrologii i psikhitarii im. S.S. Korsakova. 2008;22(S1):16-21. (In Russ.)].

29. Успенская ОВ, Яхно НН. Влияние мемантина на когнитивные функции пациентов с амнестическим вариантом синдрома умеренных когнитивных расстройств (клинико-психологическое и нейрохимическое исследование). Неврологический журнал. 2009;14(3):37-40. [Uspenskaya OV, Yakhno NN. The effect of memantine on cognitive functions of patients with the amnestic variant of the syndrome of moderate cognitive disorders (clinical-psychological and neurochemical study). Nevrologicheskii zhurnal. 2009;14(3):37-40. (In Russ.)].

30. Чердак МА, Парфенов ВА, Вахнина НВ. Дифференциальный диагноз постинсультных нервно-психических расстройств. Неврологический журнал. 2013;18(2):20-7. [Cherdak MA, Parfenov VA, Vakhnina NV. The differential diagnosis of post-stroke neuropsychiatric disorders. Nevrologicheskii zhurnal. 2013;18(2):20-7. (In Russ.)] .

31. Яхно НН, Локшина АБ, Захаров ВВ. Легкие и умеренные когнитивные расстройства при дисциркуляторной энцефалопатии. Клиническая геронтология. 2005;11(9):38-9. [Yakhno NN, Lokshina AB, Zakharov VV. Light and and moderate cognitivedisorders in dyscirculatory encephalopathy.Klinicheskaya gerontologiya. 2005;11(9):38-9.(In Russ.)].

32. Дроздова ЕА, Захаров ВВ. Когнитивные функции в остром периоде сотрясения головного мозга. Неврологический журнал. 2012;17(2):15-21. [Drozdova EA, Zakharov VV. Cognitive functions in the acute period of cerebral concussion. Nevrologicheskii zhurnal. 2012;17(2):15-21. (In Russ.)].

33. Захаров ВВ, Ярославцева НВ, Яхно НН. Когнитивные нарушения при болезни Паркинсона. Неврологический журнал. 2003;8(2):11-6. [Zakharov VV, Yaroslavtseva NV, Yakhno NN. Cognitive impairment in Parkinson's disease. Nevrologicheskii zhurnal. 2003;8(2):11-6. (In Russ.)].

34. Яхно НН. Когнитивные расстройства в неврологической клинике. Неврологический журнал. 2006;11(Приложение 1):4-12. [Yakhno NN. Cognitive disorders in neurological clinic. Nevrologicheskii zhurnal.2006;11(S1):4-12. (In Russ.)].

35. Яхно НН, Захаров ВВ. Легкие и умеренные когнитивные нарушения у пожилых. Терапевтический архив. 2006;78(1):80-3. [Yakhno NN, Zakharov VV. Light and moderate cognitive disorders in elderly. Terapevticheskii arkhiv. 2006;78(1):80-3. (In Russ.)].

36. Jessen F, Amariglio RE, van Boxtel M, et al. (Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3.

37. Захаров ВВ. Применение танакана в нейрогериатрической практике. Неврологический журнал. 1997;(5):42-9. [Zakharov VV. The use of tanakan in neurogeriatric practice. Nevrologicheskii zhurnal. 1997;(5):42-9. (In Russ.)].

38. Захаров ВВ, Яхно НН. Применение танакана при нарушении мозгового и периферического кровообращения. Русский Медицинский Журнал. 2001;9(15):645-9. [Zakharov VV, Yakhno NN. The use of tanakan in cerebral and peripheral circulation disorders. Russkii Meditsinskii Zhurnal. 2001;9(15):645-9. (In Russ.)].

39. Koltringer P, Langsteger W, Ober O. Dosedependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clinical Hemorheology. 1995;15:649–56.

40. Rosler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. J Neural Transm Suppl. 1998;54:211-9.

41. Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res. 2007 Dec;56(6):493-502. Epub 2007 Sep 15.

42. Wu Y, Wu Z, Butko P, et al. Amyloid-binduced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006 Dec 13;26(50):13102-13.

43. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002 Sep 17;99(19):12197-202. Epub 2002 Sep 4.

44. Halama P. Was leistet der Spezialextrakt (Egb 761)? Therapiewoche. 1990;40:3760-5.

45. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Epub 2012 Sep 6.

46. Тимербаева СЛ, Суслина ЗА, Бодарева ЭА и др. Танакан в лечении начальных проявлений недостаточности кровоснабжения мозга: эффективность, переносимость и отдаленные результаты. Журнал неврологии и психиатрии им. С.С.Корсакова. 1999; (8):54-61. [Timerbaeva SL, Suslina ZA, Bodareva EA, et al. Tanakan in the treatment of the initial manifestations of insufficiency of blood supply to the brain: efficacy, tolerability and long-term results. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 1999;(8):54-61. (In Russ.)].

47. Кунельская НЛ, Левина ЮВ, Красюк АА, Доронина ОМ. Оценка эффективности и переносимости танакана при лечении нейросенсорной тугоухости и ушного шума. Вестник отоларингологии. 2009;(2):40-2. [Kunel'skaya NL, Levina YuV, Krasyuk AA, Doronina OM. Evaluation of the efficacy and tolerability of tanakan in the treatment of sensorineural hearing loss and ear noise. Vestnik otolaringologii. 2009;(2):40-2. (In Russ.)].

48. Зайцева ОВ. Роль танакана в повышении эффективности вестибулярной реабилитации. Вестник отоларингологии. 2014;(5):66-8. [Zaitseva OV. The role of tanakan in enhancing the effectiveness of vestibular rehabilitation. Vestnik otolaringologii. 2014;(5):66-8. (In Russ.)].

49. Amieva H, Meillon C, Helmer C, et al. Gingko biloba extract and long term cognitive decline: a 20 years follow up population based study. PLoS One. 2013;8(1):e52755. doi: 10.1371/journal.pone.0052755. Epub 2013 Jan 11.

50. Rovio S., Kareholt I., Helkala E.L. et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol. 2005; 4(11):705-711.

51. Dartigues J.F., Gagnon M., Letenneur L. et al. Principal lifi-time occupation and cognititve impairment in French elderly cohort (PAQUID). Am J Epidemiol. 1992;135(9):981-8.

52. Scrameas N. Stern Y., Tang M.X. et al. Mediterranean diet and risk for Alzheimer’s disease. Ann Neurol. 2006;59(6):877-9.

53. Forette F., Seux M.L., Staessen J. et al. Prevention of dementia in randomized placebocontrolled systolic hypertension in Europe (SYS-EUR) trial. Lancet. 1998;352:1347-51.


For citation:


Zakharov V.V., Vakhnina N.V., Gromova D.O., Ter-Ovanesova N.E., Tarapovskaya A.V. The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):83-91. (In Russ.) https://doi.org/10.14412/2074-2711-2015-4-83-91

Views: 406


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)